Phase 3 interim analysis shows mezigdomide regimen reduced risk in relapsed/refractory myeloma
An interim phase 3 analysis showed mezigdomide plus carfilzomib and dexamethasone reduced the risk of progression or death in relapsed/refractory multiple myeloma. The SUCCESSOR-2 study remains ongoing and will assess overall survival and safety.
Mezigdomide in combination with carfilzomib and dexamethasone significantly reduced the risk of disease progression or death compared with carfilzomib and dexamethasone in an interim analysis of the phase 3 SUCCESSOR-2 trial in relapsed/refractory multiple myeloma. The oral cereblon E3 ligase modulator is being evaluated in patients who had received at least 1 prior line of anti-myeloma therapy, including prior treatment with lenalidomide and an anti-CD38 monoclonal antibody.
In the SUCCESSOR-2 trial (ClinicalTrials.gov Identifier: NCT05552976), study participants with relapsed/refractory multiple myeloma were randomly assigned to receive MeziKd or Kd. Enrolled patients had achieved minimal response or better to at least 1 prior therapy.
The primary endpoint was progression free survival. The study remains ongoing and will assess overall survival, a key secondary endpoint, as well as safety. Additional secondary endpoints include overall response rate, duration of response, time to progression, time to next treatment, minimal residual disease negativity, and health-related quality of life.
According to Bristol Myers Squibb, data from the SUCCESSOR-2 trial will be presented at a future medical meeting.
Mezigdomide is an oral CRBN-based molecular glue degrader targeting IKZF1/3 and is currently being developed by Bristol Myers Squibb. It is now in phase III trials for relapsed/refractory multiple myeloma.